All The Claims

1. A parallel coupled line filter comprising:
a parallel coupled line including first and second input ports and first and second output ports;
a first capacitor connected to the first input port of the parallel coupled line;
a second capacitor connected to the first output port of the parallel coupled line;
a third capacitor connected between the first and second input ports of the parallel coupled line; and
a fourth capacitor connected between the first and second output ports of the parallel coupled line.
2. The filter according to claim 1, wherein at least one of the second input port and the second output port is grounded.
3. The filter according to claim 1 further comprising:
a fifth capacitor connected to the second input port; and
a sixth capacitor connected to the second output port.
4. The filter according to claim 1, wherein the parallel coupled line has a length shorter than \u03bb4; and capacitances of the first and second capacitors are each determined based on the length.
5. The filter according to claim 4, wherein an even-mode characteristic impedance and an odd-mode characteristic impedance of the parallel coupled line are each determined based on the length.
6. A fabrication method of a parallel coupled line filter, the method comprising:
providing a parallel coupled line including first and second input ports and first and second output ports;
connecting a first capacitor to the first input port of the parallel coupled line;
connecting a second capacitor to the first output port of the parallel coupled line;
connecting a third capacitor between the first and second input ports of the parallel coupled line; and
connecting a fourth capacitor between the first and second output ports of the parallel coupled line.
7. The method according to claim 6 further comprising grounding at least one of the second input port and the second output port.
8. The method according to claim 6 further comprising:
connecting a fifth capacitor to the second input port; and
connecting a sixth capacitor to the second output port.
9. The method according to claim 6, wherein the parallel coupled line has a length shorter than \u03bb4; and capacitances of the first and second capacitors are each determined based on the length.
10. The method according to claim 9, wherein an even-mode characteristic impedance and an odd-mode characteristic impedance of the parallel coupled line are each determined based on the length.
11. The filter according to claim 1, further comprising:
an input line including the first input port;
an output line including the first output port; and
a transmission line coupled in parallel therebetween to at least one of the input line and the output line,
wherein the lengths of the input line and the output line are 45\xb0, the length of the transmission line is 90\xb0, and the length of the parallel coupled line is 45\xb0.
12. The method according to claim 6, further comprising:
providing an input line including the first input port, an output line including the first output port, and a transmission line coupled in parallel therebetween to at least one of the input line and the output line, wherein the lengths of the input line and the output line are 45\xb0, the length of the transmission line is 90\xb0, and the length of the parallel coupled line is 45\xb0.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An adjuvant composition comprising an immunostimulatory saponin fraction derived from the bark of Quillaja Saponaria Molina as a single HPLC peak and a sterol, with the proviso that when the adjuvant formulation comprises an ISCOM the saponin is Qs21:
2. An adjuvant composition as claimed in claim 1 wherein the immunologically active saponin fraction is derived from the bark of Quillaja Saponaria Molina is at least 90% pure.
3. An adjuvant composition as claimed in any one of claim 1, wherein the immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina is QS21.
4. An adjuvant composition as claimed in claim 1 wherein the sterol is in excess weight for weight to the immunologically active saponin fraction.
5. An adjuvant composition as claimed in any one of claim 1 wherein the ratio of saponin:sterol is from 1:100 to 1:1 (ww).
6. An adjuvant composition as claimed in claim 5 wherein the ratio of saponin:sterol is at least 1:2 (ww).
7. An adjuvant composition as claimed in claim 6, wherein the ratio of saponin:sterol is 1:5 (ww).
8. An adjuvant composition as claimed in claim 1, wherein the immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina is QS17.
9. An adjuvant composition as claimed in claim 1, wherein the sterol is cholesterol.
10. An adjuvant composition as claimed in claim 1, wherein the adjuvant composition is in the form of a vesicle.
11. An adjuvant composition as claimed in claim 10, wherein the adjuvant composition is in the form of a liposome.
12. An adjuvant composition as claimed in claim 11, wherein the adjuvant composition is in the form of a small unilamellar liposome.
13. An adjuvant composition as claimed in claim 10, wherein the adjuvant composition further comprises a phospholipid.
14. An adjuvant composition as claimed in claim 13, wherein the phospholipid is dioleoyl phosphatidylcholine.
15. An adjuvant composition comprising a saponin, a sterol, and a derivative of LPS.
16. An adjuvant composition as claimed in claim 15, wherein the LPS derivative is present in a lipid bilayer membrane.
17. An adjuvant composition as claimed in claim 15, wherein the derivative of LPS is a purified or synthetic lipid A of the following formula:
4
wherein R2 may be H or PO3H2; R3 may be an acyl chain or -hydroxymyristoyl or a 3-acyloxyacyl residue having the formula:
5
18. An adjuvant composition as claimed in claim 17, wherein the LPS derivative is 3-O-deacylated monophosphoryl lipid A.
19. An adjuvant composition comprising QS21, 3D-MPL and cholesterol.
20. An adjuvant formulation comprising a purified and stable QS21 saponin which is substantially devoid of hydrolysed QS21
21. An adjuvant formulation comprising 3D-MPL and a liposome, wherein the 3D-MPL is present in the lipid bilayer membrane.
22. An adjuvant composition as claimed in any one of claims 1 to 21, wherein the composition further comprises a carrier.
23. An adjuvant composition as claimed in claim 22, wherein the carrier is an oil in water emulsion or a metallic salt particle.
24. An adjuvant composition comprising a saponin, a sterol and a metallic salt particle.
25. An adjuvant composition as claimed in claim 24, wherein the metallic salt particle is aluminium hydroxide or aluminium phosphate.
26. An adjuvant composition as claimed in claim 24, wherein the saponin is QS21.
27. An immunogenic composition comprising an adjuvant composition as claimed in any one of claims 1 to 21, further comprising an antigen or antigenic composition.
28. An immunogenic composition comprising an adjuvant composition as claimed in claim 22, further comprising an antigen or antigenic composition.
29. A vaccine composition as claimed in any one of claims 1 to 21, further comprising an antigen or antigenic composition.
30. A vaccine composition as claimed in claim 22, further comprising an antigen or antigenic composition.
31. A vaccine as claimed in claim 29, wherein the antigen is derived from any of Human Immunodeficiency Virus, Feline Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma.
32. A vaccine as claimed in claim 30, wherein the antigen is derived from any of Human Immunodeficiency Virus, Feline Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma.
33. A vaccine as claimed in claim 29 wherein the antigen is a tumour antigen.
34. A vaccine as claimed in claim 30 wherein the antigen is a tumour antigen.
35. A method of treating a mammal suffering from or susceptible to a pathogenic infection comprising the administration of a safe and effective amount of a composition as claimed in claim 27.
36. A method of treating a mammal suffering from or susceptible to a pathogenic infection comprising the administration of a safe and effective amount of a composition as claimed in claim 28.
37. A method of treating a mammal suffering from or susceptible to a pathogenic infection comprising the administration of a safe and effective amount of a composition as claimed in claim 29.
38. A method of treating a mammal suffering from or susceptible to a pathogenic infection comprising the administration of a safe and effective amount of a composition as claimed in claim 30.
39. A method of treating a mammal suffering from cancer comprising the administration of a safe and effective amount of a composition as claimed in claim 27.
40. A method of treating a mammal suffering from cancer comprising the administration of a safe and effective amount of a composition as claimed in claim 28.
41. A method of treating a mammal suffering from cancer comprising the administration of a safe and effective amount of a composition as claimed in claim 29.
42. A method of treating a mammal suffering from cancer comprising the administration of a safe and effective amount of a composition as claimed in claim 30.
43. A process for making a vaccine composition as claimed in claim 29, comprising admixing an immunologically active saponin fraction and cholesterol with an antigen or antigenic composition.
44. A process for making a vaccine composition as claimed in claim 30, comprising admixing an immunologically active saponin fraction and cholesterol with an antigen or antigenic composition.
45. A method of inducing CTL responses in a mammal comprising administering a vaccine composition as claimed in claim 29.
46. A method of inducing CTL responses in a mammal comprising administering a vaccine composition as claimed in claim 30.
47. A method of reducing the reactogenicity of QS21 containing adjuvant formulations, by the addition of excess sterol to the adjuvant formulation (weightweight).
48. A method of stabilising QS21 against alkali mediated hydrolysis in QS21 containing adjuvant formulations, by the addition of excess sterol to the adjuvant formulation (weightweight).
49. A process for the manufacture of an adjuvant formulation comprising making small unilamellar liposomes (SUV) comprising a sterol such as cholesterol, followed by the admixture of a saponin.

1. A method of closing, sealing and dressing a wound with an adhesive applicator comprising a body with an internal reservoir, adhesive disposed in the internal reservoir and an opening between the internal reservoir and the exterior of the body; a sponge disposed over the opening; a slotted tip nozzle disposed over the sponge; and a small orifice tip nozzle disposed over the slotted tip nozzle; comprising:
closing the wound by applying small drops of adhesive to the wound, the small drops being applied by forcing the adhesive from the internal reservoir through the sponge, through the slotted tip nozzle and then through the small orifice tip nozzle;
removing the small orifice tip nozzle;
sealing the wound by applying a line of adhesive to the wound with the slotted tip nozzle;
removing the slotted tip nozzle; and
dressing the wound by applying further adhesive to the wound with the sponge.
2. The method of claim 1, wherein forcing the adhesive from the internal reservoir through the sponge, through the slotted tip nozzle and then through the small orifice tip nozzle by squeezing on the body of the applicator.
3. The method of claim 1, further comprising:
adjusting the width of the line of adhesive applied by the slotted tip nozzle by rotating the applicator, thereby rotating the slotted tip nozzle.
4. The method of claim 1, wherein the adhesive is a medical adhesive.
5. The method of claim 4, wherein the medical adhesive is a cyanoacrylate ester, in monomeric form, represented by formula I:
where R is selected from the group consisting of:
alkyl of 1 to 10 carbon atoms,
alkenyl of 2 to 10 carbon atoms,
cycloalkyl groups of from 5 to 8 carbon atoms, phenyl,
2-ethoxyethyl,
3-methoxybutyl,
and a substituent of the formula:
\u2003wherein each R\u2032 is independently selected from the group consisting of:
hydrogen and methyl, and

\u2003R\u2033 is selected from the group consisting of:
alkyl of from 1 to 6 carbon atoms,
alkenyl of from 2 to 6 carbon atoms,
alkynyl of from 2 to 6 carbon atoms,
cycloalkyl of from 3 to 8 carbon atoms,
aralkyl selected from the group consisting of benzyl, methylbenzyl and phenylethyl,
phenyl, and
phenyl substituted with 1 to 3 substituents selected from the group consisting of hydroxy, chloro, bromo, nitro, alkyl of 1 to 4 carbon atoms, and alkoxy of from 1 to 4 carbon atoms.
6. An applicator for closing, sealing and dressing a wound with liquid adhesive comprising a body with an internal reservoir capable of containing said liquid adhesive, a liquid adhesive-communicating opening between the internal reservoir and the exterior of the body; a liquid adhesive-permeable sponge disposed over the opening; a slotted tip nozzle removably disposed over the sponge; and a small orifice tip nozzle removably disposed over the slotted tip nozzle; the applicator permitting;
closure of the wound by applying small drops of the liquid adhesive to the wound to produce a closed wound, the small drops provided by passing a first portion of liquid adhesive from the internal reservoir, through the opening, through the sponge, through the slotted tip nozzle and finally through the small orifice tip nozzle to the wound:
removal of the small orifice tip nozzle to form an applicator without a small orifice tip nozzle; the applicator without a small orifice tip nozzle permitting;
sealing of the closed wound by applying a line of the liquid adhesive to the closed wound to produce a sealed wound, the line provided by passing a second portion of liquid adhesive from the internal reservoir, through the opening, through the sponge, and finally through the slotted tip nozzle to the closed wound:
and removal of the slotted tip nozzle to form an applicator without a small orifice tip nozzle or a slotted tip nozzle, the applicator without a small orifice tip nozzle or a slotted tip nozzle permitting;
dressing of the sealed wound by applying a layer of the liquid adhesive to the closed wound to produce a dressed wound; the layer provided by passing a third portion of liquid adhesive from the internal reservoir, through the opening, and finally through the sponge to the sealed wound.
7. The adhesive applicator of claim 6, wherein the small orifice tip nozzle is releasably attached to the slotted tip nozzle.
8. The adhesive applicator of claim 6, wherein the small orifice tip nozzle is releasably attached to the body.
9. The adhesive applicator of claim 6, wherein the body is such that squeezing on the body forces contents of the internal reservoir out through the opening in the applicator body.
10. The adhesive applicator of claim 6, further comprising: a medical liquid adhesive in the internal reservoir.
11. The adhesive applicator of claim 10, wherein the medical adhesive is a cyanoacrylate ester, in monomeric form, represented formula I:
where R is selected from the group consisting of:
alkyl of 1 to 10 carbon atoms,
alkenyl of 2 to 10 carbon atoms,
cycloalkyl groups of from 5 to 8 carbon atoms,
phenyl,
2-ethoxyethyl,
3-methoxybutyl,
and a substituent of the formula:
\u2003wherein each R\u2032 is independently selected from the group consisting of:
hydrogen and methyl, and

\u2003R\u2033 is selected from the group consisting of:
alkyl of from 1 to 6 carbon atoms,
alkenyl of from 2 to 6 carbon atoms,
alkynyl of from 2 to 6 carbon atoms,
cycloalkyl of from 3 to 8 carbon atoms,
aralkyl selected from the group consisting of benzyl, methylbenzyl and phenylethyl,
phenyl, and
phenyl substituted with 1 to 3 substituents selected from the group consisting of hydroxy, chloro, bromo, nitro, of alkyl 1 to 4 carbon atoms, and alkoxy of from 1 to 4 carbon atoms.
12. The adhesive applicator of claim 6, wherein the nozzle of the slotted tip nozzle has a width of between \u2153 and \u2154 of the width of the sponge.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A production printing system for processing a plurality of print jobs, the production printing system comprising:
a plurality of print job processing resources; and
a computer-readable storage medium comprising one or more programming instructions for performing a method of processing a plurality of print jobs in a document production environment, the method comprising:
identifying a print job size distribution for a plurality of print jobs in a document production environment;
determining whether the print job size distribution exhibits a heavy-tail characteristic;
for each print job size distribution exhibiting a heavy-tail characteristic:
grouping the plurality of print jobs into a plurality of subgroups such that at least one of the plurality of subgroups exhibits a non-heavy-tail characteristic, and
processing each job in the at least one of the plurality of subgroups exhibiting the non-heavy-tail characteristics with one or more of the print job processing resources.
2. The system of claim 1, wherein the print processing resources are arranged into one or more autonomous cells, wherein each autonomous cell is capable of completely processing at least one of the plurality of print jobs.
3. The system of claim 1, wherein determining whether the print job size distribution exhibits a heavy-tail characteristic is performed with a workflow management system operable to coordinate a distribution of print jobs to one or more autonomous cells.
4. The system of claim 1, wherein determining whether the print job size distribution exhibits a heavy-tail characteristic comprises one or more programming instructions for:
determining a complementary cumulative density function for the print job size distribution;
if an index of stability of the complementary cumulative density function is less than a threshold value, identifying the print job size distribution as a heavy-tailed distribution; and
if the index of stability of the complementary cumulative density function exceeds a threshold value, identifying the print job size distribution as a thin-tailed distribution.
5. The system of claim 4, further comprising setting the threshold value in a range of 0-2.
6. The system of claim 1, in which the print job size distribution has a minimum print job size value and a maximum print job size value, wherein grouping the plurality of print jobs comprises one or more programming instructions for:
selecting a job size threshold value between the minimum print job size value and the maximum print job size value;
splitting the print job size distribution into a first distribution segment and a second distribution segment based on the selected job size threshold value; and
determining whether the first distribution segment exhibits a heavy-tail characteristic.
7. The system of claim 6, further comprising corresponding the first and second distribution segments with a right-most distribution segment and a left-most distribution segment, respectively.
8. The system of claim 1, in which each one of the plurality of print jobs corresponds with a print job type, further comprising:
analyzing historical variation associated with each job type over a processing interval; and
using the historical variation to optimize a configuration of one or more autonomous cells.
9. The system of claim 1, in which each one of the plurality of print jobs corresponds with one or more print job types, wherein grouping the plurality of print jobs includes forming at least one of the plurality of subgroups on the basis of a historical variation in volume over a processing interval associated with the corresponding print Job types.
10. The system of claim 1 in which each one of the plurality of print jobs corresponds with a print job type, further comprising:
determining a coefficient of variation for a demand distribution for a selected print job type;
comparing the coefficient of variation to a threshold coefficient;
if the coefficient of variation exceeds the threshold coefficient, identifying the selected job type as a high-variability job type; and
if the coefficient of variation does not exceed the threshold coefficient, identifying the selected job type as a low-variability job type.
11. The system of claim 10, further comprising configuring one of the one or more autonomous cells to correspond with the low variability job type.
12. A method of processing a plurality of jobs in a production environment, the method comprising:
identifying, with a computer, a job size distribution for a plurality of jobs in a production environment;
determining, with the computer, whether the job size distribution exhibits a heavy-tail characteristic;
for each job size distribution exhibiting a heavy-tail characteristic:
grouping the plurality of jobs into a plurality of subgroups such that at least one subgroup does not exhibit a heavy-tail characteristic,
configuring one or more job processing resources in the production environment for one or more of the subgroups that do not exhibit the heavy-tail characteristic, and
processing the one or more subgroups that do not exhibit the heavy-tail characteristic with the one or more job processing resources.
13. The method of claim 12, further comprising arranging the job processing resources into one or more autonomous cells wherein each autonomous cell is capable of completely processing at least one of the plurality of jobs.
14. The method of claim 12, wherein determining whether the job size distribution exhibits a heavy-tail characteristic comprises:
determining a complementary cumulative density function for the job size distribution;
if an index of stability of the complementary cumulative density function is less than a threshold value, identifying the job size distribution as a heavy-tailed distribution; and
if the index of stability of the complementary cumulative density function exceeds the threshold value, identifying the job size distribution as a thin-tailed distribution.
15. The method of claim 14, further comprising setting the threshold value in a range of 0-2.
16. The method of claim 12, in which the job size distribution has a minimum job size value and a maximum job size value, wherein grouping the plurality of jobs comprises:
selecting a job size threshold value between the corresponding minimum job size value and the corresponding maximum job size value;
splitting the job size distribution into a plurality of distribution segments based on the selected job size threshold value; and
determining whether the right-most distribution segment exhibits a heavy-tail characteristic.
17. The method of claim 16, wherein determining whether any of the plurality of distribution segments exhibits a heavy-tail characteristic comprises, for each distribution segment:
determining a cumulative density distribution function;
if an index of stability of the complementary cumulative distribution function is less than a threshold value, identifying the distribution segment as a heavy-tailed distribution; and
if an index of stability of the complementary cumulative distribution function exceeds the threshold value, identifying the distribution segment as a thin-tailed distribution.
18. The method of claim 12, wherein processing one or more subgroups comprises:
identifying the jobs associated with a subgroup, wherein each job has a job type;
selecting a job type; and
analyzing a characteristic of the selected job type over a processing interval.
19. The method of claim 18, wherein analyzing a characteristic of the selected job type comprises:
determining a coefficient of variation for the selected job type;
comparing the coefficient of variation to a threshold coefficient;
if the coefficient of variation exceeds the threshold coefficient, identifying the selected job type as a high-variability job type; and
if the coefficient of variation does not exceed the threshold coefficient, identifying the selected job type as a low-variability job type.
20. The method of claim 19, further comprising:
if the selected job type is a low-variability job type, designing an autonomous cell to process the selected job type, wherein the autonomous cell includes one or more resources in the document production environment necessary to process the selected job type.